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INTRODUCTION: Diabetes mellitus (DM) is a complication of chronic pancreatitis (CP). Whether pancreatogenic
diabetes associated with CP-DM represents a discrete pathophysiologic entity from type 2 DM
(T2DM) remains uncertain. Addressing this question is needed for development of specific
measures tomanage CP-DM.We approached this question from a unique standpoint, hypothesizing
that if CP-DM and T2DM are separate disorders, they should be genetically distinct. To test
this hypothesis, we sought to determine whether a genetic risk score (GRS) based on validated
single nucleotide polymorphisms for T2DM could distinguish between groups with CP-DM and
T2DM.
METHODS: We used 60 T2DM single nucleotide polymorphisms to construct a weighted GRS in 1,613 subjects
from the North American Pancreatitis Study 2 and 2,685 subjects from the Multi-Ethnic Study of
Atherosclerosis, all of European origin.
RESULTS: ThemeanGRSwas identical between321 subjectswith CP-DMand423 subjectswith T2DM (66.53 vs
66.42,P50.95), and theGRSof both diabetic groupswas significantly higher than that of nondiabetic
controls (n 5 3,554, P < 0.0001). Exploratory analyses attempting to enrich the CP-DM group for
pancreatogenic diabetes, such as eliminating diabetes diagnosed before CP, requiring pancreas-
specific comorbidities, or removing those with a family history of diabetes, did not improve the ability of
the GRS to distinguish between CP-DM and T2DM.
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DISCUSSION: Recognizing that we lacked a gold standard to define CP-DM, our study suggests that CP-DM may be
a subtype of T2DM, a notion that should be tested in future, large prospective studies.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A59
Clinical and Translational Gastroenterology 2019;10:e-00057. https://doi.org/10.14309/ctg.0000000000000057
INTRODUCTION
While diabetes mellitus (DM) arising as a result of diseases of the
exocrine pancreas has come to be known as type 3c DM, we
recently proposed that it be classified based on the underlying
disorder, as mechanisms of hyperglycemia likely differ between
pancreatic disorders (1). Of the pancreatic diseases associated
with pancreatogenic DM, pancreatitis is the most common, ac-
counting for up to 80% of cases, of which ;80% are acute pan-
creatitis and ;20% are chronic pancreatitis (CP), with smaller
percentages caused by pancreatic ductal adenocarcinoma (;18%)
and cystic fibrosis (;2%) (2). CP is a progressive fibroin-
flammatory syndrome with multiple etiologies and variable char-
acteristics of atrophy,fibrosis, pain syndromes, duct distortion and
strictures, calcifications, and pancreatic exocrine dysfunction (3).
The prevalence of diabetes in patients with CP (herein, designated
CP-DM) is approximately 30%–40% and is increased in patients
with concurrent alcohol use, longer duration of CP, and after
pancreatic surgery (4–8). Some patients with CP never develop
CP-DM, however, suggesting that other modifying genetic and
environmental factors are important (9–11). Indeed, patients with
CP with obesity, a family history of diabetes, or African ancestry
are at a higher risk of CP-DM than patients with CPwithout these
risk factors for type 2 DM (T2DM) (4). However, this does not
account for the high prevalence of diabetes in CP, nor provides
insight into the underlying mechanisms of beta-cell dysfunction.
Pancreatogenic DM is often unrecognized and misdiagnosed
as type 1 DM (T1DM) or T2DM (12,13). Among 31,789 new
cases of adult-onset diabetes, 1.8% occurred after a diagnosis of
acute or CP (and were therefore likely to be pancreatogenic DM),
which exceeded the proportion of new cases of T1DM (1.1%)
(13). Furthermore, those with pancreatogenic DM had higher
hemoglobin A1c levels and required insulin earlier than those
with typical T2DM. This illustrates the clinical importance of
distinguishing pancreatogenic DM from T2DM, as the former
may require more intensive care (11,14).
Disease subclassification is important to facilitate targeted
treatment in diabetes, with the best-known example being T1DM
vs T2DM. Differentiating the various types of maturity-onset
diabetes of the young (MODY) is another example. MODY
caused by heterozygous mutations in the glucokinase gene
(MODY2) has a mild phenotype and usually does not require
treatment (15). Other types of MODY usually progress to severe,
often insulin-requiring diabetes. Of the latter, identification of
those withmutations inHNF1A (MODY3) orHNF4A (MODY1)
is crucial because these patients have excellent glycemic responses
to sulfonylurea therapy (16).
MODY illustrates the role genetics can play in classifying
different subtypes of diabetes. Genome-wide association studies
(GWAS) have provided numerous robust loci that can be ag-
gregated into genetic risk scores (GRSs) that can be used to ef-
fectively distinguish between common types of diabetes. Despite
the modest proportion of heritability explained by GWAS single
nucleotide polymorphisms (SNPs), GRSs based on SNPs for
T1DM or T2DM have been found to separate groups of indi-
vidualswith these 2 disorders (17). GRSs based onT1DMvariants
were able to discernMODY from T1DM in infants with neonatal
diabetes (18). Furthermore, GRS analysis concluded that latent
autoimmune diabetes of adults (LADA) is a form of T1DM,
rather than a distinct disorder (19).
Given successes in the use of GWAS-derived variants in GRSs
to clarify diabetes subtypes, either confirming that 2 conditions
are distinct (T1DMandT2DM) or aremanifestations of the same
underlying pathophysiology (T1DM and LADA), we used
a similar strategy in the current study, examining whether a GRS
based onT2DMvariants could differentiate CP-DM fromT2DM.
METHODS
Subjects
The current study is based on 2 established and previously gen-
otyped cohorts. The first is the North American Pancreatitis
Study 2 (NAPS2), a cross-sectional case-control cohort study in 3
phases (NAPS2 original, NAPS2 Continuation and Validation
[NAPS2-CV], and NAPS2 Ancillary Study [NAPS2-AS]) with
samples collected between 2000 and 2014 that were used to
conduct the first GWAS for CP (20) and other studies (4).
Methodology and data collection procedures for the NAPS2 have
been previously described (21). Herein, diabetes was defined in
the NAPS2 based on the physician questionnaire response or
patient self-report. Subjects (n 5 1,613) who had undergone
genome-wide genotyping were selected for the current study.
Subjects with diabetes and CP or recurrent acute pancreatitis
(RAP) were considered to have CP-DM. The NAPS2 provided
734 cases of CP, of which 246 had diabetes, and 438 cases of RAP,
of which 75 had diabetes. In addition, 441 subjects without
pancreatic disease (53 with diabetes) were also studied. Figure 1
illustrates the categorization of the study participants. All subjects
are of European ancestry (previously confirmed using genetic
data (20)). Regarding a subset of NAPS2 participants with di-
abetes and pancreatitis (n 5 168), the physician questionnaire
also classified diabetes as preexisting if diagnosed over 2 years
before CP or RAP, as concurrent if diagnosed within 2 years
before CP or RAP diagnosis, and as after CP or RAP when di-
agnosed after the CP or RAP diagnosis. For the subjects with CP,
duration of disease was defined as the difference between the age
of enrollment and the age at the first attack of acute pancreatitis,
age at the first onset of symptoms, or age at diagnosis of CP,
whichever came first. Duration of RAP was taken as the age at
enrollment minus the age at the first attack of acute pancreatitis.
These variables were combined as duration of pancreatic disease.
The second cohort was the Multi-Ethnic Study of Athero-
sclerosis (MESA). The MESA is a population-based longitudinal
investigation of subclinical cardiovascular disease and its pro-
gression, wherein a total of 6,814 individuals, aged 45–84 years at
baseline, were recruited from 6 US communities between 2000
and 2002 and followed at 5 subsequent examinations, with the last
follow-up visit occurring from 2016 to 2018 (22). Thirty-eight









percent of the participants were white, 28% African American,
22% Hispanic, and 12% Asian. The MESA sample size was in-
creased to over 7,000 by the MESA Air study initiated in 2004
(23). For the current effort, only subjects of non-Hispanic Eu-
ropean origin from the MESA and MESA Air (n 5 2,685, of
whom 370 had diabetes) were selected to match the de-
mographics of the NAPS2 (Figure 1). Diabetes was defined as the
use of glucose-lowering medication or having a fasting blood
glucose $7.0 mmol/L (126 mg/dL). In the current study, we in-
cluded in the diabetic group those with prevalent and incident
diabetes. The MESA subjects with diabetes and the NAPS2 sub-
jects with diabetes butwithout pancreatic diseasewere considered
to have typical T2DM.
For both cohorts, all participants gave written informed
consent before their inclusion in research studies, and all studies
were overseen by the relevant institutional review boards.
Genotyping and SNP selection
Subjects from the NAPS2 were genotyped on the Illumina
OmniExpress beadchip, as previously described (20). The MESA
was genotyped using the Affymetrix SNP 6.0 SNP Array, with
imputation using the 1000 Genomes Project reference panel
(phase 1, version 3) as reference, as previously described (24). At
this time, imputation has not yet been completed in the NAPS2.
Therefore, selection of T2DM SNPs initially focused on finding
SNPs that were represented on the OmniExpress chip, compris-
ing either the index SNPs or SNPs in linkage disequilibrium (r2$
0.8) with the index SNPs. The list of SNPs available in the NAPS2
was then cross-referenced to the MESA.
The primary source of data for SNP selection was a 2014
GWAS meta-analysis involving several diabetes genetics con-
sortia (not including the MESA or NAPS2), which represented
the most extensive analysis at the time the current study was
conceived (25). As that GWAS included multiple ancestry
groups, we focused on 73 independent (r2. 0.1) SNPs associated
with T2DM from that study for which European-specific odds
ratios (ORs) were reported (based on 12,171 T2DM cases and
74,124 controls). Of those, 67 were represented on the
OmniExpress chip and were successfully genotyped in the
NAPS2. We retained 60 of the original 67 SNPs that were asso-
ciated with T2DMat genome-wide significance (P, 53 1028) in
GWAS data from a very large European GWAS for T2DM
(56,862 T2DM cases and 824,006 controls) (26) that became
available during the course of our study. Supplemental Table 1
(see Supplementary Digital Content 1, http://links.lww.com/
CTG/A59) lists the 60 SNPs ultimately studied herein.
Statistical analysis
GRSs were constructed based on the 60 SNPs described above,
focusing on the alleles of each SNP that were associated with
an increased risk of T2DM. Allele counts (0, 1, and 2) were
used for directly genotyped SNPs, and dosage was used for im-
puted SNPs. We computed a weighted GRS as follows:
GRS5 n3 ½ðSNP1 3 effect size1Þ1 ðSNP2 3 effect size2Þ1…
1 ðSNPn 3 effect sizenÞ=the sum of the effect sizes, where
n is the number of SNPs, SNPi is the number or dosage of
T2DM-increasing alleles, and effect sizes were the natural log of
the ORs. As recommended by best practices (27), we updated
the ORs using results from the largest available T2DM GWAS
(26). Using the same methods, a subset of 32 and 14 of the
T2DM SNPs were used to construct a beta-cell function GRS
and an insulin resistance GRS, respectively, based on functional
assignments of these T2D SNPs from the literature (28,29)
(see Table 1, Supplementary Digital Content 1, http://links.
lww.com/CTG/A59).
Demographics (age and body mass index [BMI]) and GRS
between groups were compared using Student t tests (when
comparing 2 groups, e.g., NAPS2 vs MESA) and one-way
ANOVA with the Tukey honestly significant difference (HSD)
post hoc test (when comparing more than 2 groups, e.g., no di-
abetes vs T2DM vs CP-DM). Chi square tests were used to
compare sex and obesity between groups. Because it was not
normally distributed, BMI was log transformed for all analyses;
however, untransformed values are presented in tables to facili-
tate interpretation. Logistic regressionmodels were used to adjust
for age, sex, and BMI by including them as independent variables
along with the GRS in models where the dependent variable
compared the nondiabetic group with the T2DM group, the
nondiabetic group with the CP-DM group, or the T2DM group
with the CP-DM group.
Our sample size had 80% power (2 tailed, alpha 0.05) to detect
a difference in mean 60 SNP-based GRS of 0.76 between the
nondiabetic group and the T2DM group, mean difference of 0.85
between the nondiabetic group and the CP-DM group, andmean
difference of 1.09 between the T2DM and CP-DM groups.
RESULTS
Demographic characteristics of the 2 cohorts are presented in
Table 1. The sex distribution was identical between the cohorts,
whereas mean BMI was higher in the MESA than in the NAPS2.
Mean age was greater in the MESA, a result of the recruitment
scheme of this cohort. Similar patterns between cohorts for age,
sex, and BMI were seen when stratified by presence or absence of
diabetes (Table 1). Table 2 compares groups without diabetes,
with T2DM, and with CP-DM. The higher age of the T2DM
groupwas partly a consequence of the large proportion of subjects
from the MESA in this group. The proportion of men was higher
Figure 1. Flowchart of subject distribution. The chart outlines the numbers
of subjects from the2cohortswhowere categorizedas nondiabetic, T2DM,
or CP-DM. CP-DM, chronic pancreatitis–diabetes mellitus; MESA, Multi-
Ethnic Study of Atherosclerosis; NAPS2, North American Pancreatitis
Study 2; RAP, recurrent acute pancreatitis; T2DM, type2 diabetesmellitus.
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in both diabetes groups compared with the nondiabetic group.
While BMIwas higher only in the T2DMgroup, the proportion of
obese subjects differed between all groups.
The mean GRS was identical between the 2 cohorts (Table 1).
The mean GRS was similar between 2,315 nondiabetic individ-
uals from the MESA and 1,239 nondiabetic individuals from the
NAPS2 (65.33 vs 65.02, P5 0.093), serving as a negative control
and supporting the validity of the use of the GRS in joint analyses
of the 2 cohorts. As a positive control, themeanGRSwas found to
be significantly greater in those with T2DM than those without
diabetes (66.42 vs 65.23,P, 0.0001) (Table 2). TheOR for T2DM
vs no diabetes for each unit increment in the GRS was 1.043 (95%
confidence interval [CI] 1.024–1.064, P , 0.0001), which was
similar after adjustment for age, sex, and BMI (OR 1.049, 95% CI
1.029–1.071, P , 0.0001). In a further positive control analysis,
we randomly removed nondiabetic subjects such that their
numberwas the same as that of thosewithCP-DM(n5 321). The
423 subjects with T2D still had greater mean GRS than this re-
duced number of controls (66.42 vs 65.00, P 5 0.0004), demon-
strating that the discriminative power of the GRS was not driven
by the large number of nondiabetic controls.
The mean GRS of those with CP-DM did not differ from that
of those with T2DM, whereas it was significantly greater than
those without diabetes (Figure 2 and Table 2). Quantitatively
similar results were seen in analyses stratifying the cohort into
weight categories (lean, overweight, and obese) (Table 3). These
differences were also evident in logistic regression models that
adjusted for age, sex, and BMI, wherein the OR for each unit
increment in the GRS for T2DM vs CP-DM was 0.996 (95% CI
0.966–1.027, P5 0.80), whereas for CP-DM vs no diabetes, it was
1.051 (95%CI 1.028–1.074, P, 0.0001). CP-DM and T2DM also
did not differ in terms of the beta-cell GRS or the insulin re-
sistance GRS, which displayed similar patterns to the overall GRS
(Table 4).
Recognizing that some subjects labeled as having CP-DM
based on having CP or RAP and diabetes may actually have
T2DM, we conducted a series of exploratory analyses wherein we
attempted to enrich the CP-DM group for pancreatogenic DM.
First, we examined the timing of the diabetes diagnosis relative to
the diagnosis of CP or RAP. A subgroup was formed by excluding
those with preexisting diabetes (diagnosed.2 years before CP or
RAP). The GRS between this subset, presumably enriched for
pancreatogenic DM, did not differ from the GRS of those with
T2DM (Table 5), whereas their GRS remained higher than the
GRS of subjects without diabetes (Table 5).
In another effort to enrich the CP-DM group for pancreato-
genic DM, we defined a CP-DM group by requiring the presence
of at least one pancreas-related comorbidity or complication that
we previously found to be associated with diabetes in the NAPS2,
including pancreatic calcification, pancreatic atrophy, exocrine
insufficiency, or pancreatic surgery (4). We also examined CP-
DM groups based on having each of these factors individually. In
no case did the CP-DM group characterized by any pancreas-
related comorbidity have a significantly different GRS than the
Table 1. Demographics and GRSs by cohort
All subjects MESA (n 5 2,685) NAPS2 (n 5 1,613) P value
Age (yr) 62.7 6 10.2 49.9 6 15.8 ,0.0001
Female, n (%) 1,400 (52.1) 844 (52.3) 0.91
BMI (kg/m2) 27.8 6 5.1 26.2 6 5.9 ,0.0001
Obese, n (%) 750 (28) 349 (22) ,0.0001
GRS 65.52 6 5.24 65.31 6 5.40 0.20
Diabetes MESA (n5 370) NAPS2 (n 5 374) P value
Age (yr) 63.2 6 9.6 54.5 6 14.7 ,0.0001
Female, n (%) 159 (43.0) 163 (43.6) 0.87
BMI (kg/m2) 31.4 6 5.8 27.9 6 6.8 ,0.0001
Obese, n (%) 190 (51) 163 (44) ,0.0001
GRS 66.69 6 5.27 66.25 6 5.51 0.26
No diabetes MESA (n 5 2,315) NAPS2 (n 5 1,239) P value
Age (yr) 62.7 6 10.2 48.5 6 15.9 ,0.0001
Female, n (%) 1,241 (53.6) 681 (55.0) 0.91
BMI (kg/m2) 27.2 6 4.8 25.8 6 5.5 ,0.0001
Obese, n (%) 560 (24) 231 (19) 0.0005
GRS 65.33 6 5.21 65.02 6 5.34 0.093
Data are presented asmean6 SD for quantitative traits and number of subjects
(percent) for female sex and obesity (defined as BMI$30 kg/m2). P values are
derived from Student t tests for quantitative traits and x2 for female sex and
obesity.
BMI, body mass index; GRS, genetic risk score; MESA, Multi-Ethnic Study of
Atherosclerosis; NAPS2, North American Pancreatitis Study 2.
Table 2. Demographics and GRSs by diabetes status
No diabetes (n 5 3,554) T2DM (n5 423) CP-DM (n5 321)
P value (no diabetes
vs T2DM)




Age (yr) 57.7 6 14.2 62.7 6 10.7 53.8 6 14.5 ,0.0001 ,0.0001 ,0.0001
Female, n (%) 1922 (54) 188 (44) 134 (42) 0.0002 ,0.0001 0.46
BMI (kg/m2) 26.7 6 5.1 31.2 6 5.9 27.5 6 6.8 ,0.0001 0.26 ,0.0001
Obese, n (%) 791 (22) 214 (51) 94 (29) ,0.0001 0.0055 ,0.0001
GRS 65.23 6 5.26 66.42 6 5.38 66.536 5.42 ,0.0001 ,0.0001 0.95
Data are presented asmean6SD for quantitative traits andnumber of subjects (percent) for female sex and obesity (defined asBMI$30 kg/m2). For the quantitative traits,
all one-way ANOVAP valueswere,0.0001;post hocTukeyHSDP values are reported in the table for pairwise comparisons. Chi-squareP values are reported for female sex
and obesity.
BMI, bodymass index; CP-DM, chronic pancreatitis–diabetesmellitus; GRS, genetic risk score; T2DM, type 2 diabetesmellitus; NAPS2, North American Pancreatitis Study 2.









T2DM group (Table 5). In most cases, the CP-DM subgroups
demonstrated significantly highermeanGRSs than those without
diabetes (Table 5).
Our previous study also found that canonical risk factors for
T2DM, namely being overweight or obese or having a family
history of diabetes, were strong predictors of diabetes in the
NAPS2 (4). Therefore, to deplete the CP-DM group of subjects
with T2DM, we constructed subgroups of CP-DM that were lean
(BMI , 25 kg/m2) or who had no family history of diabetes. As
shown in Table 5, these measures also did not differentiate the
GRS of those with CP-DM from the GRS of those with T2DM.
Finally, we stratified the CP-DM group by the median dura-
tion (4 years) of pancreatic disease at the time of enrollment in the
NAPS2. Both the CP-DM subgroup with shorter duration of
disease (less than 4 years) and the CP-DM subgroup with longer
duration of disease (4 years ormore) had similarmeanGRS as the
T2DM group (Table 5).
DISCUSSION
The premise of our study is that GRSs based on robust GWAS
SNPs can differentiate between different types of diabetes. This has
been observed forT1DMvsT2DM.AGRSbased on30variants for
T1DMwas able to discriminate between T1DMand T2DM in 223
young adults aged 20–40 years (17). Among 3,887 individuals, risk
scores for T1DM (30 SNPs) or T2DM (69 SNPs) were able to
discriminate between the 2 types of diabetes (17). A GRS based on
T1DM variants was used to estimate the prevalence of T1DM in
a sample of 13,250 individuals who had developed diabetes in the
first 6 decades of life; those identified by the T1DMGRS had lower
BMI, earlier insulin requirement, and higher rates of diabetic
ketoacidosis than thosewithT2DM(30). In a cohort of infantswith
neonatal diabetes, the T1DM GRS was able to distinguish MODY
fromT1DM (18). Another study determined GRSs for T1DM and
T2DM in young adults with clinically defined T1DM, LADA, or
T2DM (19). Genetically, those with T1DM and LADA were in-
distinguishable, suggesting that LADA is a particular presentation
of T1DM, rather than a distinct condition or an intermediate trait
between T1DM and T2DM. Thus, not only can the GRS separate
different types of diabetes, it may also reveal whether certain types
arise from similar etiologies.
Our results suggest that from the standpoint of T2DM genetic
variants, CP-DM and T2DM are similar. This suggests that CP-
DMmay be a particular presentation of T2DM, similar to LADA
being a type of T1DM. Indeed, we previously found that indi-
viduals with CP-DM were more likely to be overweight or obese
and have a family history of diabetes compared with those with
CP and no diabetes (4). We also found that pancreas-specific
factors including exocrine insufficiency, atrophy, calcifications,
and pancreas surgeryweremore likely inCPwith diabetes than in
CP without diabetes.
How may CP-DM be conceptualized in the framework of the
pathophysiology of T2DM? Two key features lie at the heart of
T2DM: insulin resistance and insufficient compensatory hyper-
insulinemia. Insulin resistance arises largely because of lifestyle and
environmental factors. Several studies also have suggested that
insulin resistance (both whole body (31–34) and hepatic (34,35))
may also be a feature of pancreatogenic DM (11). Most individuals
with insulin resistance respond with compensatory increases in
beta-cell insulin production, raising circulating insulin levels to
overcome tissue insulin resistance and maintain normoglycemia.
Those individuals who cannot sustain this hyperinsulinemic
compensation go on to develop impaired glucose tolerance and
ultimately T2DM (36). The mechanisms underlying beta-cell
failure in typical T2DM are multifactorial and remain to be fully
determined (37). In setting ofCP-DM, the additional insult of beta-
cell dysfunction and ultimately loss resulting from chronic in-
flammation and pancreatic fibrosis likely contribute to beta-cell
failure and an inability to compensate for insulin resistance, as
supported by ourfinding that pancreas-specific factors increase the
Table 3. GRSs stratified by weight category
Stratum
Percent of
cohort No diabetes GRS T2DM, GRS CP-DM, GRS
P value (no diabetes
vs T2DM)






Lean 37.3% 65.32 6 5.18 65.536 5.44 66.38 6 5.27 0.95 0.067 0.56 0.083
Overweight 25.6% 65.25 6 5.32 67.036 5.03 67.03 6 4.75 0.0002 0.0038 0.99 ,0.0001
Obese 36.4% 65.02 6 5.28 66.226 5.58 66.34 6 6.16 0.012 0.066 0.98 0.0032
Data are presented asmean6 SD for the GRS. Overall P values are from one-way ANOVA; post hoc Tukey HSD P values are reported in the table for pairwise comparisons.
Lean is defined as BMI ,25 kg/m2, overweight as BMI $25 and,30 kg/m2, and obese as BMI $30 kg/m2. BMI was not available in 32 subjects from the NAPS2.
BMI, body mass index; CP-DM, chronic pancreatitis–diabetes mellitus; GRS, genetic risk score; T2DM, type 2 diabetes mellitus.
Figure2.GRSbydiabetes status. The contour plots depict the data density,
with horizontal width representing frequency. ThemeanGRS (indicated by
black dots) was similar in those with T2DM and CP-DM, whereas themean
GRS of both diabetes groups was higher than the GRS of the nondiabetic
group. Error bars reflect SE. CP-DM, chronic pancreatitis–diabetes
mellitus; GRS, genetic risk score; T2DM, type 2 diabetes mellitus.
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odds for diabetes in CP (4). The model shown in Figure 3 depicts
CP-DM in the context of T2DM.
A common assumption is that CP-DMarises simply from islet
destruction and therefore represents primarily a disorder of ab-
solute insulin deficiency accompanied by glucagon and pancre-
atic polypeptide deficiency. Although this is true in advanced
cases of CP, evidence suggests that beta-cell dysfunctionmay arise
early in the course of CP, well before islet destruction (38,39). A
potential mechanism is that products of activated stellate cells or
toxic factors produced in the diseased exocrine pancreas enter the
islets and disturb beta-cell function, with inflammatory cytokines
being likely candidates (40). Reduction in beta-cell mass on his-
tology and reduced glucose-stimulated insulin release were
documented in nondiabetic patients with advanced CP (41). A
mechanism of beta-cell failure that does not involve massive
destruction, but rather progressive dysfunction, fits well with the
model in Figure 3. On the other hand, fulminant advanced CP
may bypass the typical T2DM pathophysiology and lead directly
to insulin-deficient diabetes.
We have not ruled out the possibility that CP-DM is a separate
condition from T2DM because the definition of T2DM is broad.
In CP, the stress on the islets may cause early beta-cell dysfunc-
tion and unmask T2DM, as suggested by our results using the
GRS of T2DM SNPs. However, other genes may exist that are
more specific for CP-DM that were not included in the current
GRS. Because the prevalence of diabetes is much higher in
patients withCP than age-matched controls, the group of patients
withCP and diabetes likely represents a heterogeneousmixture of
etiologies, including T2DM, CP-DM, loss of islet mass from
surgery, pancreatic necrosis or destruction, and potentially
patients with a combination of conditions. Such heterogeneity
could have reduced the ability of the GRS to separate this group
from the group of individuals with typical T2DM. Physiologic
tests directed at discriminating pancreatogenic DM from T2DM,
such as reduced pancreatic polypeptide response to mixed-
nutrient ingestion (11), were not performed in the NAPS2. We
conducted several exploratory analyses wherein we attempted to
enrich the CP-DM group for pancreatogenic DM or deplete the
Table 5. GRSs in various CP-DM subgroups compared with the GRS in T2DM and in those without diabetes









No diabetes 3,554 65.23 21.19 ,0.0001 0 NA
T2DM 423 66.42 0 NA 1.19 ,0.0001
CP-DM 321 66.53 0.11 0.95 1.30 ,0.0001
CP-DM with diabetes after CP or RAP 127 67.00 0.58 0.51 1.77 0.0005
CP-DM with any pancreatic comorbidity 252 66.29 20.13 0.95 1.06 0.0056
CP-DM with pancreatic calcifications 152 66.30 20.12 0.97 1.07 0.036
CP-DM with pancreatic atrophy 104 66.47 0.05 0.99 1.24 0.047
CP-DM with exocrine insufficiency 136 65.84 20.58 0.50 0.61 0.38
CP-DM with pancreatic surgery 81 65.53 20.89 0.35 0.30 0.86
CP-DM with BMI ,25 kg/m2 129 66.38 20.04 0.99 1.15 0.039
CP-DM with no family history of diabetes 132 66.03 20.39 0.74 0.80 0.19
CP-DM with shorter duration of pancreatic
disease
146 66.96 0.54 0.53 1.74 0.0003
CP-DM with longer duration of pancreatic
disease
163 66.14 0.28 0.84 0.92 0.078
For duration of pancreatic disease, shorter duration is less than 4 years and longer duration is 4 years ormore. Statistically significant differences are highlighted in bold. All
one-way ANOVA P values were ,0.0001; post hoc Tukey HSD P values are reported in the table for pairwise comparisons.
BMI, body mass index; CP-DM, chronic pancreatitis–diabetes mellitus; GRS, genetic risk score; NA, not applicable; RAP, recurrent acute pancreatitis; T2DM, type 2
diabetes mellitus.







P value (no diabetes
vs T2DM)






Beta-cell GRS 33.98 6 4.00 34.85 6 4.29 34.84 6 4.20 ,0.0001 0.0007 0.99 ,0.0001
Insulin resistance GRS 16.55 6 2.42 16.80 6 2.32 16.95 6 2.50 0.11 0.012 0.67 0.0037
Data are presented asmean6 SD for the GRS. Overall P values are from one-way ANOVA; post hoc Tukey HSD P values are reported in the table for pairwise comparisons.
The beta-cell GRS was constructed as the weighted sum of T2DM risk alleles at 32 SNPs implicated in beta-cell function; the insulin resistance GRS is based on 14 T2DM
SNPs implicated in insulin resistance.
CP-DM, chronic pancreatitis–diabetes mellitus; GRS, genetic risk score; SNP, single nucleotide polymorphism; T2DM, type 2 diabetes mellitus.









CP-DM group of T2DM. Although none of these subgroup
analyses could differentiate the CP-DM GRS from the T2DM
GRS, the subgroups were generally small in sample size, limiting
discriminative power. Results from the current study involving
CP may not apply to pancreatogenic DM with other underlying
conditions such as pancreatic adenocarcinoma or cystic fibrosis.
The prevalence of DM associated with CP increases with the
duration of disease, from 8% to 10% at the time of CP diagnosis to
over 80%20–25 years later (6,7). InNAPS2 subjects withCP-DM,
the duration of CP or RAP covered a wide range, from the di-
agnosis being made at enrollment to 40 years before enrollment
(median 4 years). We conducted subgroup analyses to determine
whether CP-DMexhibited a different genetic profile in thosewith
shorter- or longer-term pancreatic disease. In neither case did the
mean GRS differ from those with T2DM, suggesting that the
genetic similarity between CP-DM and T2DM applies irre-
spective of the duration of underlying pancreatic disease.
GRSs stratified by weight category (Table 3) exhibited differ-
ences by diabetes status that were generally similar to those in the
entire cohort. An exception was the lack of difference in the GRS
between lean patients with T2DM and those without diabetes.
Given the relatively highmedian BMI (27 kg/m2) of participating
cohorts in the GWAS that provided the SNPs for our GRS (25), it
is tempting to propose that the SNPs are relevant toT2DMonly in
overweight or obese individuals.However, we believe that the lack
of difference was a chance finding due to the lownumber (n5 57)
of individuals with T2DM in the lean stratum.
Regardless of whether the underlying pathophysiology of CP-
DM differs from that of T2DM, our study has potential clinical
implications. Although our goal was not to assess the ability of
a T2D GRS to predict CP-DM, our results suggest that among
patients with CP of variable underlying etiologies, those with
heightened genetic risk for T2DM are at a higher risk of CP-DM.
Thus, in a personalized medicine approach, GRSs composed of
T2DM variants may be used to risk stratify patients with CP,
prompting closer surveillance or measures to prevent diabetes.
Given the numerically small differences in mean GRSs between
those with and without diabetes, consistent with observations in
several other adult-onset polygenic conditions, focusing on those
with extreme GRS values (e.g., top quintile) and integrating ge-
netics with clinical risk factors may prove most useful for per-
sonalized risk stratification (42). Until further research is
conducted on diabetes prevention in CP, lifestyle modification or
metformin, which have been proven to prevent T2DM in people
withprediabetes (43,44), couldbeoffered topatientswithCPat high
genetic risk of diabetes. Metformin is a particularly attractive agent,
given that observational studies suggest that it may prevent pan-
creatic cancer (45), which is a potential complication of CP. These
potential uses of metformin would be investigational (not US Food
and Drug Administration-approved indications). Other modalities
to prevent diabetes in CP may arise from future genetic or physi-
ologic research, either in typical T2DM or specific to CP-DM.
This study is the first to genetically compare CP-DM and
T2DM. The GRS, composed solely of T2DM SNPs from GWAS,
does not represent the overall role of genetics that would be
expected from whole genome sequencing and comprehensive
analysis of all known genetic variants linked to the complex
pathobiology of pancreatic disease and/or diabetes. The most re-
cent GWAS analysis for T2DM identified over 400 SNPs (26);
however, given that most (.80%) of these are not present on the
OmniExpress chip, we will not be able to examine them until
imputation has been performed in theNAPS2 data set. The sample
sizes may be considered modest by GWAS standards; however,
given the greater power of the GRS over single SNPs, the GRS
herein was able to distinguish between patients with and without
diabetes, with similar effect sizes to other studies examining GRS
association with T2DM (28). A possible limitation is that a much
larger sample size may be needed to detect a subtle genetic differ-
ence between T2DM and CP-DM, especially if the latter group
consists of a heterogeneous mix of both conditions. Such hetero-
geneity is likely, given that 24% (41 of 168) of those in the CP-DM
grouphad diabetes that preceded pancreatitis, and that in 48% (153
of 321), the timing of these diagnoses was unknown. Another
limitation is the lack of a gold standard method to diagnose CP-
DM, which led to classification of all patients with CP herein with
diabetes as having CP-DM. The fact that diabetes diagnosis was
made in theNAPS2 by physician questionnaire response or patient
self-report, rather than by objective laboratorymeasures, is another
weakness.We also acknowledge that a small proportion of subjects
from theMESAwho have diabetes (assumed herein to have typical
T2DM) may have pancreatic disease and CP-DM. The effects of
this on the current results are expected to be negligible, given that
the proportion of occult CP-DM within MESA subjects with di-
abetes is likelymuch smaller than the proportion ofCP-DMwithin
NAPS2 subjects with diabetes.
In conclusion, genetic risk based on robust T2DM variants
does not separate patients with T2DM from CP-DM, suggesting
that diabetes in CP/RAP may represent a subtype of T2DM,
Figure 3. Pathophysiology of CP-DM in the context of T2DM. Early in the pathogenesis of T2DM, insulin resistance arises as a result of lifestyle and
environmental factors and genetics, with excess adiposity contributing in many cases. Failure of beta-cell function to compensate for insulin resistance is
the key event leading to diabetes. Beta-cell failure in typical T2DM ismultifactorial and has a strong genetic component. The figure presents amodel of CP-
DMwithin this pathophysiologic framework, where several features (genetic risk, family history, and obesity) are sharedwith typical T2DM. Although excess
adiposity contributes to insulin resistance in some cases, the proportion of obesity is expected to be lower in CP-DM than T2DM (Table 2). The pancreas-
specific factors are proposed to contribute to the beta-cell failure that leads to CP-DM. CP-DM, chronic pancreatitis–diabetes mellitus; T2DM, type 2
diabetes mellitus.
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where dysfunction, destruction, or removal of the exocrine pan-
creas is responsible for the beta-cell failure that precipitates di-
abetes in patients who are at an increased risk of beta-cell
decompensation. Additional genetic risk factors that are mech-
anistically linked to CP cannot be ruled out in this study. Our
consortium is conducting a prospective study of the natural
history of CP (46), which will allow us to validate the current
results and evaluate the predictive value of the T2DM GRS in
incident CP-DM. Future studies will focus on genetic and phys-
iologic definitions of pancreatogenic DM (47) toward the needed
goal of better prevention and management of this previously
under-recognized form of diabetes.
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